Stifel analyst Annabel Samimy said that her review of the meeting materials prepared ahead of the upcoming FDA advisory committee meeting to review Horizon Pharma's application for approval of teprotumumab give her confidence in a positive outcome on risk/benefit. The comments and questions suggest that the FDA is comfortable with the drug's efficacy and the majority of questions surround the safety profile, stated Samimy, who added that "overall, the questions are broad and not geared toward any new/specific concerns." She keeps a Buy rating and $35 price target on Horizon Pharma shares.